Voyager Therapeutics (VYGR)
(Delayed Data from NSDQ)
$7.62 USD
+0.20 (2.70%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $7.62 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VYGR 7.62 +0.20(2.70%)
Will VYGR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VYGR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VYGR
Novavax (NVAX) Surges 8.4%: Is This an Indication of Further Gains?
Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More
VYGR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Voyager (VYGR) Gains on Gene Therapy Deal With Novartis
Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates
Voyager Therapeutics (VYGR) Moves 7.9% Higher: Will This Strength Last?
Other News for VYGR
Commit To Purchase Voyager Therapeutics At $5, Earn 12.4% Annualized Using Options
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
Optimistic Buy Rating for Voyager Therapeutics Amid Strong Pipeline and Strategic Partnerships
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
Voyager announces selection of development candidate for GBA1 Program